1. Home
  2. PRLD vs FURY Comparison

PRLD vs FURY Comparison

Compare PRLD & FURY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • FURY
  • Stock Information
  • Founded
  • PRLD 2016
  • FURY 2008
  • Country
  • PRLD United States
  • FURY Canada
  • Employees
  • PRLD N/A
  • FURY N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • FURY Precious Metals
  • Sector
  • PRLD Health Care
  • FURY Basic Materials
  • Exchange
  • PRLD Nasdaq
  • FURY Nasdaq
  • Market Cap
  • PRLD 73.7M
  • FURY 59.1M
  • IPO Year
  • PRLD 2020
  • FURY N/A
  • Fundamental
  • Price
  • PRLD $1.39
  • FURY $0.40
  • Analyst Decision
  • PRLD Strong Buy
  • FURY Strong Buy
  • Analyst Count
  • PRLD 2
  • FURY 1
  • Target Price
  • PRLD $4.50
  • FURY $2.00
  • AVG Volume (30 Days)
  • PRLD 783.6K
  • FURY 130.4K
  • Earning Date
  • PRLD 02-13-2025
  • FURY 11-12-2024
  • Dividend Yield
  • PRLD N/A
  • FURY N/A
  • EPS Growth
  • PRLD N/A
  • FURY N/A
  • EPS
  • PRLD N/A
  • FURY N/A
  • Revenue
  • PRLD $3,000,000.00
  • FURY N/A
  • Revenue This Year
  • PRLD N/A
  • FURY N/A
  • Revenue Next Year
  • PRLD N/A
  • FURY N/A
  • P/E Ratio
  • PRLD N/A
  • FURY N/A
  • Revenue Growth
  • PRLD N/A
  • FURY N/A
  • 52 Week Low
  • PRLD $0.80
  • FURY $0.32
  • 52 Week High
  • PRLD $6.80
  • FURY $0.59
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 60.84
  • FURY 52.04
  • Support Level
  • PRLD $1.12
  • FURY $0.36
  • Resistance Level
  • PRLD $1.48
  • FURY $0.44
  • Average True Range (ATR)
  • PRLD 0.18
  • FURY 0.02
  • MACD
  • PRLD 0.05
  • FURY 0.00
  • Stochastic Oscillator
  • PRLD 74.78
  • FURY 70.15

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.

Share on Social Networks: